Cabaletta Bio (NASDAQ:CABA – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08, MarketWatch Earnings reports.
NASDAQ:CABA traded up $0.17 during midday trading on Friday, reaching $1.49. 118,402 shares of the company traded hands, compared to its average volume of 172,872. Cabaletta Bio has a twelve month low of $1.17 and a twelve month high of $14.95. The company has a fifty day moving average price of $1.74 and a 200 day moving average price of $4.84.
A number of large investors have recently added to or reduced their stakes in CABA. Bank of New York Mellon Corp boosted its position in Cabaletta Bio by 120.2% during the 1st quarter. Bank of New York Mellon Corp now owns 22,674 shares of the company’s stock valued at $46,000 after purchasing an additional 12,379 shares during the period. Walleye Trading LLC bought a new stake in Cabaletta Bio during the 4th quarter valued at $87,000. Cubist Systematic Strategies LLC raised its stake in Cabaletta Bio by 112.4% during the 4th quarter. Cubist Systematic Strategies LLC now owns 22,880 shares of the company’s stock valued at $87,000 after acquiring an additional 12,106 shares in the last quarter. Northern Trust Corp raised its stake in Cabaletta Bio by 17.4% during the 4th quarter. Northern Trust Corp now owns 29,307 shares of the company’s stock valued at $111,000 after acquiring an additional 4,337 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Cabaletta Bio during the 4th quarter valued at $151,000. Institutional investors and hedge funds own 62.75% of the company’s stock.
Cabaletta Bio Company Profile (Get Rating)
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- Get a free copy of the StockNews.com research report on Cabaletta Bio (CABA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.